01—Abstract
Summary
Summary of the 10-K filed April 10, 1998. Cited figures are marked; the original filing is the authoritative source.
Neurocrine Biosciences, Inc. (NBIX) reported its 10-K for fiscal year ended December 31, 1997.
The company describes itself as a neuroimmunology company developing therapeutics for central nervous and immune system diseases, with all product candidates in research or early development and no regulatory approval requested or received for any product. Its lead programs include CRF receptor antagonists (Janssen, Phase I for anxiety and depression), CRF-binding protein antagonists (Lilly, for obesity and Alzheimer's), altered peptide ligands for multiple sclerosis (Novartis, Phase II), and DHEA for Alzheimer's (Phase II/III in Canada and other countries). Financially, total revenues rose to $26.1 milliona in 1997 from $19.2 million in 1996, driven by sponsored research, milestones and other revenues, while research and development expense increased to $19.9 million from $12.6 million.
Net income declined to $5.1 millionb, or $0.28 per diluted share, from $5.9 million, or $0.36 per diluted share, in 1996. Cash, cash equivalents and short-term investments totaled $75.1 million at year-end, and management states that existing resources, together with interest income and future alliance payments, should fund operations at least through 2000.
The company has no product revenues and relies on its three collaborations for funding. The filing also discloses a February 27, 1998 letter of intent to acquire Northwest NeuroLogic, Inc. in a 100% stock transaction valued at approximately $4.0 millionc.
02—Key points
Key Highlights
- Total revenues of $26.1 million in 1997, up from $19.2 million in 1996, driven by sponsored research, milestones and other revenues.
- Net income of $5.1 million ($0.28 diluted EPS) in 1997, down from $5.9 million ($0.36 diluted EPS) in 1996, mainly due to higher R&D spending.
- Research and development expense rose to $19.9 million from $12.6 million, reflecting growth in CRF and altered peptide ligand programs.
- Cash, cash equivalents and short-term investments of $75.1 million at December 31, 1997; management expects resources to last at least through 2000.
- Three strategic alliances: Janssen (CRF receptor antagonists), Novartis (altered peptide ligands for MS, with $15.7 million received in license fees and research funding), and Eli Lilly (CRF-binding protein ligand inhibitors, with $22.0 million in expected research payments).
- Lead DHEA program for Alzheimer's is in a physician-IND Phase II trial and a Phase II/III trial in Canada and other countries; the company has no approved products.
- Subsequent event: letter of intent signed February 27, 1998 to acquire Northwest NeuroLogic, Inc. in a 100% stock deal valued at about $4.0 million.
03—Questions
Frequently Asked Questions
Does Neurocrine have any products approved or generating sales?
No. The filing states the company has not requested or received regulatory approval for any product, has not generated product revenues, and does not expect product revenues for the foreseeable future. Its revenues come from strategic alliances.
How much has the company's revenue depended on its collaboration partners?
Revenue is primarily from sponsored research, milestones and other revenues under the Janssen, Novartis and Eli Lilly collaborations. The filing states the company is dependent on its corporate partners for funding certain programs, and that termination of any alliance could have a material adverse effect.
Why did net income decline in 1997 despite higher revenue?
Operating expenses grew faster than revenue. Research and development expense increased to $19.9 million from $12.6 million, and general and administrative expense rose to $5.7 million from $3.7 million, as the company expanded research, clinical and administrative activity.
How long is the company's cash expected to last?
Management believes existing capital resources, together with interest income and future payments under the strategic alliances, will be sufficient to satisfy current and projected funding requirements at least through 2000. The filing also notes that additional funding may be needed and that no assurance of adequate funding can be given.
What is the status of the company's lead programs?
The CRF receptor antagonist for anxiety and depression entered Phase I trials in late 1997 under Janssen. The altered peptide ligand for multiple sclerosis has completed Phase I and began Phase II patient accrual in the latter half of 1997. The DHEA program for Alzheimer's is in a physician-IND Phase II trial whose results are expected in mid-1998, and a Phase II/III trial in Canada and other countries that is expected to be completed by the end of 1998.
04—Continue